Evidence map›Paper›PMID 42028437›Full record

ArticleFrontiers in pharmacology2026

Discovery of potent and highly selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for treating diabetic nephropathy.

Haotian Ni, Yifei Geng, Shan Xu, Yuting Wang, Dong Sun, Fengzhen Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haotian Ni *Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yifei Geng *Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, Jiangsu, China.
Shan Xu *Clinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yuting WangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, Jiangsu, China.
Dong SunClinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Fengzhen WangDepartment of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of glucose reabsorption by SGLT2 in the kidney is a promising strategy for the treatment of diabetic nephropathy. Adverse side effects of SGLT1 inhibition can be reduced by selective inhibition of SGLT2. Here, we developed an integrated virtual screening approach (combining drug-likeness analysis, pharmacophore model recognition, molecular docking experiments, and interaction analysis) to discover novel SGLT2 inhibitors.

Indexed as

biological evaluationdiabetic nephropathypharmacophore modelingsodium-glucose cotransporter 2virtual screening

Identifiers

PMID42028437
PMCPMC13099297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.